PYXS Nasdaq· Pyxis Oncology Inc
FundamentalsNews digest Peer analysis
PYXS Nasdaq· Pyxis Oncology Inc
Earnings report Q3 2023

Pyxis Oncology Reports Decreased Revenue in Latest Quarter

Segments of Revenue

Pyxis Oncology reported a decline in revenue for the latest quarter. The company's revenue can be broken down into two segments: research and development and general and administrative expenses.

  • Research and development expenses amounted to $14.69 million for the quarter, compared to $19.03 million in the same period last year. This represents a decrease of approximately 23%.
  • General and administrative expenses totaled $10.67 million, slightly higher than the $9.36 million reported in the previous year's quarter.


Despite the decrease in revenue, Pyxis Oncology's management highlighted several strengths in their financial performance. They emphasized the progress made in their research and development efforts, which resulted in a reduction in expenses compared to the previous year. This indicates improved efficiency in the company's operations. Additionally, the company's ability to generate sublease income of $598,000 during the quarter contributed to their overall financial performance.


The main weakness in Pyxis Oncology's financial performance was the decline in revenue. The decrease in revenue can be attributed to the reduction in research and development expenses, which may indicate a slowdown in the company's pipeline development. Additionally, the increase in general and administrative expenses compared to the previous year's quarter suggests higher operating costs, which could impact profitability.


It is worth noting that Pyxis Oncology reported a net loss of $23.05 million for the quarter, compared to a net loss of $27.67 million in the same period last year. This improvement in net loss can be attributed to the decrease in operating expenses and the increase in other income, primarily driven by interest and investment income.


Pyxis Oncology's latest quarter performance was characterized by a decline in revenue, primarily driven by a decrease in research and development expenses. However, the company demonstrated strengths in their financial performance, including improved efficiency in operations and the generation of sublease income. The main challenge for Pyxis Oncology lies in addressing the decline in revenue and managing their operating costs effectively. Overall, the company's financial performance showed signs of improvement, as evidenced by the decrease in net loss compared to the previous year's quarter.

Source documents

Form 10-Q  filed on Nov 07, 2023
7 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS beat by 10.53%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.